Cytovation to Evaluate Getacatetide (CY-101) in Combination with Tislelizumab in CRC
“Checkpoint inhibitors have transformed the treatment landscape in many cancers. Unfortunately, the vast majority of colorectal cancer patients with liver metastases remain without an effective immunotherapy option. The liver is a critical immunological bottleneck – a site where anti-tumor immunity is actively suppressed, blunting the benefit of checkpoint blockade,” said Lars Prestegarden, Co-founder and CEO of Cytovation. “This supply agreement allows us to directly assess getacatetide’s ability to address this challenge, harness the full potential of PD-1 inhibition and potentially deliver a powerful dual therapeutic combination in this large and underserved patient population.”
Share:
More News
Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20
“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of
“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence
“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib